Clinical Trials
21 trialsA Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Memorial Sloan Kettering Cancer Center
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Radium-223 in Biochemically Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Rad2Nivo
University of Utah
BAT-RAD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
RAVENS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
PEACE III
European Organisation for Research and Treatment of Cancer - EORTC
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Dana-Farber Cancer Institute
AlphaBet
Peter MacCallum Cancer Centre, Australia
EXCAAPE
MedSIR
RAPSON
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
TRANCE
University Health Network, Toronto
CARE
GenesisCare USA
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
CORE-OCU
Osaka City University
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
University of Michigan Rogel Cancer Center